FGAM
IBRX icon

Financial Gravity Asset Management’s ImmunityBio IBRX Stock Holding History

Financial Gravity Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17
Closed -$94 – 1602
2024
Q1 		$94 Buy
17
+15
+750% +$68 ﹤0.01% 967
2023
Q4 		$11 Buy
+2
New +$6 ﹤0.01% 1273

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Financial Gravity Asset Management's IBRX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 17 shares — an estimated $94 sold.

Financial Gravity Asset Management first reported a position in IBRX in Q4 2023 and held it in 2 quarters. The position peaked at $94 in Q1 2024. 194 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 17 ImmunityBio shares in Q2 2024, an estimated $94.
  • Financial Gravity Asset Management first reported a position in ImmunityBio in Q4 2023 and held it in 2 quarters.
  • Financial Gravity Asset Management's ImmunityBio position peaked at $94 in Q1 2024.
  • 194 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.